(c) introducing a helper virus to the population of cells of step (b); [and

(d) selecting a cell exhibiting helper-virus-inducible rep protein activity.] wherein said cell exhibits helper virus-inducible expression of said stably integrated AAV rep gene.

3. (Amended) A method according to claim 1, wherein said packaging cell [is capable of growing] grows at least one half as rapidly as parental-type cells that do not contain an AAV rep gene, and wherein said packaging cell when used to package rAAV vectors [is capable of packaging rAAV vectors to produce] produces at least 100 rAAV particles/cell.

6. (Amended) A cell produced by the method of claim 1, and progeny thereof, wherein said cell exhibits helper virus-inducible expression of said stably integrated AAV rep gene.

7. (Amended) A cell produced by the method of claim 3, and progeny thereof, wherein said cell exhibits helper virus-inducible expression of said stably integrated AAV rep gene.

8. (Amended) A cell produced by the method of claim 4, and progeny thereof, wherein said cell exhibits helper virus-inducible expression of said stably integrated AAV rep gene.

9. (Amended) A cell produced by the method of claim 5, and progeny thereof, wherein said cell exhibits helper virus-inducible expression of said stably integrated AAV rep gene.

10. (Amended) A mammalian cell [capable of high efficiency] for packaging of a recombinant AAV (rAAV) vector, said cell comprising a stably integrated cap gene operably linked to a promoter, and a stably integrated rep gene operably linked to a helper virus-inducible heterologous promoter; wherein p5 promoter function has been replaced by the helper virus-inducible heterologous promoter and wherein said cell exhibits helper-virus-inducible [rep protein activity] expression of said stably integrated AAV rep gene.

11. (Amended) An AAV packaging cell of claim 10, wherein said helper-virus-inducible [rep protein activity] expression of said stably integrated AAV rep gene is inducible by adenovirus.

12. (Amended) An AAV packaging cell of claim 10, wherein said packaging cell [is capable of growing] grows at least one half as rapidly as parental-type cells that do not contain an AAV rep gene, and wherein said packaging cell when used to package rAAV vectors [is capable of packaging rAAV vectors to produce] produces at least 100 rAAV particles/cell.

15. (Amended) An AAV packaging cell of claim 10, further comprising a stably integrated recombinant AAV (rAAV) vector, said vector comprising a polynucleotide sequence of interest located between two AAV inverted terminal repeat (ITR) regions, wherein said polynucleotide is operably linked to a promoter.

16. (Amended) A method of packaging a recombinant AAV vector, comprising the steps of:

(a) providing an AAV packaging cell of claim 10;

(b) introducing a recombinant AAV (rAAV) vector, said vector comprising a polynucleotide sequence of interest located between two AAV inverted terminal repeat (ITR) regions, wherein said polynucleotide is operably linked to a promoter;

(c) introducing a helper virus; and

(d) incubating the cell under conditions suitable for replication and packaging of AAV such that said rAAV vector is packaged.

17. (Amended) A method of packaging a recombinant AAV vector, comprising the steps of:

(a) providing an AAV packaging cell of claim 15 which comprises a stably integrated rAAV vector comprising a polynucleotide of interest operably linked to a promoter;

(b) introducing a helper virus; and

(c) incubating the cell under conditions suitable for replication and packaging of AAV such that said rAAV vector is packaged.

21. (Amended) A method of determining the [relative] infectious titer of an rAAV vector preparation, comprising the steps of:

(a) introducing a helper virus and serial dilutions of the rAAV vector preparation to AAV packaging cells of claim 10;

(b) incubating the cells under conditions suitable for replication of AAV; and

determining the amount of replicated rAAV vector relative to an rAAV preparation of known titer.

Please add new claim 22 as follows:

22. (New) The method of claim 1, further comprising the step of selecting a cell exhibiting helper-virus-inducible expression of said stably integrated AAV rep gene.